Tanai Therapeutics

Gent ·KBO/BCE: BE 1002.228.546

Loading dossier…

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	22-05-2026	70 d early	2026-00118405
31-12-2024	31-07-2025	03-06-2025	58 d early	2025-00119008

Metric	This company	Sector median	Position in the sector
Solvency	91.8%	49.8%	better than 95% of 81 sector peers
Net result	€-2.49M	€17k	better than 5% of 80 sector peers
Equity	€3.56M	€102k	better than 91% of 81 sector peers
Gross operating margin	€-528k	€49k	better than 5% of 76 sector peers
Total assets	€3.87M	€250k	better than 87% of 81 sector peers

Line item	Code	2025
Balance sheet, Assets
TOTAL ASSETS	20/58	€3.87M
Fixed assets	21/28	€884k
Intangible fixed assets	21	€850k
Tangible fixed assets	22/27	€34k
Current assets	29/58	€2.99M
Amounts receivable within one year	40/41	€72k
Cash & bank	54/58	€2.73M
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€3.87M
Equity	10/15	€3.56M
Contributions / capital	10/11	€7.85M
Accumulated profits (losses)	14	€-4.29M
Amounts payable	17/49	€316k
Amounts payable within one year	42/48	€316k
Trade debts payable within one year	44	€316k
Income statement
Gross operating margin	9900	€-528k
Operating result	9901	€-2.57M
Financial income	75	€46k
Financial charges	65	€5k
Result before taxes	9903	€-2.53M
Income taxes	67/77	€-45k
Net result for the period	9904	€-2.49M
Result to be appropriated	9905	€-2.49M

Summary

NACE primary	Speur- en ontwikkelingswerk op biotechnologisch gebied(72101)
Legal form	Public limited company(014)
Incorporation	13-11-2023
Status	Active
Postal code	9051